Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- GUBRA.CO
- Price
- 432.00
- Stock movement down
- -10.00 (-2.26%)
- Company name
- Gubra A/S
- Exchange
- (CO ,
- Currency
- DKK )
- Sector
- Healthcare >Biotechnology
- Market cap
- 7.05B
- Ent value
- 7.15B
- Price/Sales
- 31.48
- Price/Book
- 15.19
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -0.38%
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- 53.74%
- 3 year return
- -
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-03-29
DIVIDENDS
GUBRA.CO does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 31.48 |
| Price to Book | 15.19 |
| EV to Sales | 31.92 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 16.31M |
| EPS (TTM) | -2.77 |
| FCF per share (TTM) | -0.22 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 223.81M |
| Gross profit (TTM) | 131.47M |
| Operating income (TTM) | -51.04M |
| Net income (TTM) | -46.53M |
| EPS (TTM) | -2.77 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | 58.74% |
| Operating margin (TTM) | -22.80% |
| Profit margin (TTM) | -20.79% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 46.91M |
| Net receivables | 31.07M |
| Total current assets | 492.26M |
| Goodwill | 0.00 |
| Intangible assets | 13.83M |
| Property, plant and equipment | 0.00 |
| Total assets | 610.76M |
| Accounts payable | 14.81M |
| Short/Current long term debt | 91.46M |
| Total current liabilities | 67.99M |
| Total liabilities | 146.88M |
| Shareholder's equity | 463.88M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -25.39M |
| Capital expenditures (TTM) | 18.77M |
| Free cash flow (TTM) | -3.66M |
| Dividends paid (TTM) | 14.00K |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -10.03% |
| Return on Assets | -7.62% |
| Return on Invested Capital | -9.75% |
| Cash Return on Invested Capital | -0.77% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 441.00 |
| Daily high | 442.00 |
| Daily low | 431.00 |
| Daily Volume | 22K |
| All-time high | 728.00 |
| 1y analyst estimate | 800.00 |
| Beta | - |
| EPS (TTM) | -2.77 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| GUBRA.CO | S&P500 | |
| Current price drop from All-time high | -40.66% | -9.34% |
| Highest price drop | -42.56% | -56.47% |
| Date of highest drop | 5 Nov 2024 | 9 Mar 2009 |
| Avg drop from high | -12.56% | -11.07% |
| Avg time to new high | 10 days | 12 days |
| Max time to new high | 117 days | 1805 days |
COMPANY DETAILS
Marketcap
7.05B
Marketcap category
Mid-cap
Description
Gubra A/S operates as a biotech company with two primary areas of business: pre-clinical contract research (CRO) services and proprietary early target and drug discovery programs in Denmark and internationally. The company operates through CRO, Discovery & Partnerships, and Gubra Green segments. It offers pre-clinical contract research and development services within metabolic and fibrotic diseases for the pharmaceutical and biotechnology industry, as well as provides services in vivo pharmacology, assays and molecular pharmacology, bioinformatics, bioanalysis, next gen sequencing, and 2D and 3D imaging. The company has a partnership and collaboration with Boehringer Ingelheim to discover novel peptides for the treatment of obesity. Gubra A/S was incorporated in 2008 and is based in Horsholm, Denmark.
Employees
235
Website
Investor relations
-
SEC filings
CEO
Country
Denmark
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
HØRSHOLM, DK / ACCESS Newswire / March 28, 2025 / Gubra (CPH:GUBRA) With reference to AbbVie's (NYSE:ABBV) and Gubra A/S' (CPSE:GUBRA) joint announcement of March 3, 2025 regarding a license agreement...
March 28, 2025
HØRSHOLM, DK / ACCESS Newswire / March 10, 2025 / Gubra (CPH:GUBRA) Notice to convene ANNUAL GENERAL MEETING 2025 GUBRA A/SCVR NO. 30 51 40 41 To the shareholders of Gubra A/S (CVR no. 30 51 40 41), n...
March 10, 2025
AbbVie and Gubra Announce License Agreement to Develop an Amylin Analog for the Treatment of Obesity
HØRSHOLM, DK / ACCESS Newswire / March 03, 2025 / Gubra (CPH:GUBRA) Partnership marks AbbVie's entrance into the obesity field Agreement will enable the incorporation of GUB014295, an amylin peptide d...
March 3, 2025